Following undergraduate training at Cambridge University, Dr O’Sullivan undertook postgraduate training at The Royal Brompton National Heart & Lung Hospital and the Oxford University Teaching Hospitals. He returned to Cambridge in 1996 to complete higher cardiological training with particular emphasis on interventional cardiology. During this period he was awarded a PhD, and the British Cardiac Society Young Research Worker's Prize, for research into mechanisms of coronary stent failure. From 2003-2004, he worked in the Department of Interventional Cardiology at University of British Columbia, Vancouver and gained extensive experience in advanced interventional techniques and new strategies for the treatment of coronary disease.
Dr O’Sullivan was appointed Consultant Cardiologist at Royal Papworth Hospital and Addenbrooke's Hospitals in 2004. In this position he provides secondary and tertiary centre care to patients with general cardiac problems (valve disease, heart failure, heart rhythm problems etc.), in addition to those with coronary disease.
Whilst maintaining a busy clinical practice, Dr O’Sullivan has a major role in medical management, having been appointed Clinical Director of the Addenbrooke's Cardiology Department in 2006. He serves as regional specialty advisor for Cardiology to the British Cardiovascular Society and the Royal College of Physicians. In addition, he remains active in the research arena, with interests in the invasive assessment and treatment of coronary disease and the exciting field of percutaneous mitral valve repair.
Interventional cardiology (angiography, angioplasty, coronary stenting), valvular heart disease (assessment and percutaneous treatment)
Novel techniques for invasive treatment of coronary artery disease.
Coronary physiology.
Mechanisms of coronary stent failure (in-stent stenosis / restenosis).
Intracoronary ultrasound and virtual histology.
Percutaneous mitral valve repair.
To view Dr O'Sullivan's clinical outcomes, please click on this link. This will take you to the British Cardiovascular Intervention Society website which is not part of the Papworth Hospital website.
BA (Class I Hons, Cantab), 1990
MB BChir (Distinctions, Cantab), 1992
MA (Cantab), 1994
MRCP (London), 1996
PhD (Cantab), 2002
FRCP (London), 2009
Fellow of the Royal College of Physicians, London
Member of British Cardiovascular Society
Member of British Cardiovascular Intervention Society
Registered with General Medical Council
Specialist Advisor to National Institute for Health and Clinical Excellence
Calvert PA, Obaid DR, O'Sullivan M, Shapiro LM, McNab D, Densem CG, Schofield PM, Braganza D, Clarke SC, Ray KK, West NE, Bennett MR. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. (2011) JACC Cardiovasc Imaging 4(8): 894-901
Calvert PA, Liew TV, Gorenne I, Clarke M, Costopoulos C, Obaid DR, O'Sullivan M, Shapiro LM, McNab DC, Densem CG, Schofield PM, Braganza D, Clarke SC, Ray KK, West NE, Bennett MR. Leukocyte tleomere length is associated with high risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity.
(2011) Arterioscler Thromb Vasc Biol. 31(9):2157-64
Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP.A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. (2011) Circ Cardiovasc Interv. 4(3):266-72
Hoole SP, Heck PM, White PA, Read PA, Khan SN, West NE, O'Sullivan M, Dutka DP. Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans: insights from simultaneous coronary and left ventricular haemondynamic assessment. (2010) JACC Cardiovasc Interv. 3(4):412-8.
Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in coronary stenting (CRISP stent) study: a prospective, randomized control trial. (2009) Circulation 119(6):820-7
Hoole SP, Heck PM, White PA. Khan SN, O'Sullivan M, Clarke SC, Dutka DP.Remote ischemic preconditioning stimulus does not reduce microvascular resistance or improve myocardial blood flow in patients undergoing elective percutaneous coronary intervention. (2009) Angiology 60(4):403-11.
Hoole SP, Khan SN, White PA, Heck PM, Kharbanda RK, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Remote ischaemic preconditioning does not attenuate ischaemic left ventricular dysfunction in humans. (2009) Eur J Heart Fail 11(5):497-505
Hoole SP, White PA, Heck PM, Khan SN, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Primary coronary microvascular dysfunction and poor coronary collaterals predict post-PCI cardiac necrosis.
(2009) Coron Artery Dis. 20(4):253-9.
O'Sullivan M, Scott SD, McCarthy N, Figg N, Shapiro LM, Kirkpatrick P Bennett MR. Differential cyclin e expression in human in-stent stenosis vascular smooth muscle cells identifies targets for selective anti-restenosis therapy. (2003). Cardiovascular research 60: 673-83.
Scott S, O'Sullivan M, Hafizi S, Shapiro LM, Bennett MR.Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: implications for brachytherapy and drug treatment for restenosis. (2002). Circ res 90: 398-404.
O'Sullivan M, Bennett MR. Gene therapy for coronary restenosis: is the enthusiasm justified? (2001). Heart 86: 491-493.
Bennett MR & O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy.
(2001). Phamacol therapeutics 91: 149-166.
